Cargando…
Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma?
PURPOSE: Up to 10% of recurrences develop beyond 5 years after curative treatment of localized renal cell carcinoma (RCC). Clinicopathologic features were evaluated to determine which factors are associated with late recurrence. MATERIALS AND METHODS: A total of 753 patients were diagnosed with loca...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506106/ https://www.ncbi.nlm.nih.gov/pubmed/25622589 http://dx.doi.org/10.4143/crt.2014.013 |
_version_ | 1782381646799962112 |
---|---|
author | Lee, Sang Hyub Son, Hee Seo Cho, Seok Kim, Sang Jin Yoo, Dae Seon Kang, Seok Ho Park, Sung Yul Park, Jinsung Chang, Sung-Goo Jeon, Seung Hyun |
author_facet | Lee, Sang Hyub Son, Hee Seo Cho, Seok Kim, Sang Jin Yoo, Dae Seon Kang, Seok Ho Park, Sung Yul Park, Jinsung Chang, Sung-Goo Jeon, Seung Hyun |
author_sort | Lee, Sang Hyub |
collection | PubMed |
description | PURPOSE: Up to 10% of recurrences develop beyond 5 years after curative treatment of localized renal cell carcinoma (RCC). Clinicopathologic features were evaluated to determine which factors are associated with late recurrence. MATERIALS AND METHODS: A total of 753 patients were diagnosed with localized RCC from January 2000 to June 2008. We enrolled 225 patients who were treated surgically and had a minimal recurrence-free survival of 60 months. Patients who had recurrence beyond 5 years after nephrectomy were defined as the late recurrence group and the remaining patients as the recurrence-free group. Multivariate logistic regression analyses and the Cox proportional hazard model were used for determination of features associated with late recurrence. RESULTS: In multivariate analyses, age older than 60 (p=0.030), Fuhrman grade ≥ 3 (p=0.042), and pT stage ≥ pT2 (p=0.010) showed statistical association with late recurrence. The Cox proportional hazard model showed significant differences in recurrence-free survival when we classified the patients based on pT2 (p=0.007) and on patient age ≥ 60 years (p=0.039). CONCLUSION: Patient age greater than 60 years, Fuhrman grade ≥ 3, and tumor stage ≥ pT2 are independent risk factors of recurrence more than 5 years after surgery in patients with RCC. Therefore, close lifelong follow-up is recommended for patients with these risk factors. |
format | Online Article Text |
id | pubmed-4506106 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-45061062015-07-21 Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma? Lee, Sang Hyub Son, Hee Seo Cho, Seok Kim, Sang Jin Yoo, Dae Seon Kang, Seok Ho Park, Sung Yul Park, Jinsung Chang, Sung-Goo Jeon, Seung Hyun Cancer Res Treat Original Article PURPOSE: Up to 10% of recurrences develop beyond 5 years after curative treatment of localized renal cell carcinoma (RCC). Clinicopathologic features were evaluated to determine which factors are associated with late recurrence. MATERIALS AND METHODS: A total of 753 patients were diagnosed with localized RCC from January 2000 to June 2008. We enrolled 225 patients who were treated surgically and had a minimal recurrence-free survival of 60 months. Patients who had recurrence beyond 5 years after nephrectomy were defined as the late recurrence group and the remaining patients as the recurrence-free group. Multivariate logistic regression analyses and the Cox proportional hazard model were used for determination of features associated with late recurrence. RESULTS: In multivariate analyses, age older than 60 (p=0.030), Fuhrman grade ≥ 3 (p=0.042), and pT stage ≥ pT2 (p=0.010) showed statistical association with late recurrence. The Cox proportional hazard model showed significant differences in recurrence-free survival when we classified the patients based on pT2 (p=0.007) and on patient age ≥ 60 years (p=0.039). CONCLUSION: Patient age greater than 60 years, Fuhrman grade ≥ 3, and tumor stage ≥ pT2 are independent risk factors of recurrence more than 5 years after surgery in patients with RCC. Therefore, close lifelong follow-up is recommended for patients with these risk factors. Korean Cancer Association 2015-07 2014-11-17 /pmc/articles/PMC4506106/ /pubmed/25622589 http://dx.doi.org/10.4143/crt.2014.013 Text en Copyright © 2015 by the Korean Cancer Association This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lee, Sang Hyub Son, Hee Seo Cho, Seok Kim, Sang Jin Yoo, Dae Seon Kang, Seok Ho Park, Sung Yul Park, Jinsung Chang, Sung-Goo Jeon, Seung Hyun Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma? |
title | Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma? |
title_full | Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma? |
title_fullStr | Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma? |
title_full_unstemmed | Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma? |
title_short | Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma? |
title_sort | which patients should we follow up beyond 5 years after definitive therapy for localized renal cell carcinoma? |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506106/ https://www.ncbi.nlm.nih.gov/pubmed/25622589 http://dx.doi.org/10.4143/crt.2014.013 |
work_keys_str_mv | AT leesanghyub whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma AT sonheeseo whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma AT choseok whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma AT kimsangjin whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma AT yoodaeseon whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma AT kangseokho whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma AT parksungyul whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma AT parkjinsung whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma AT changsunggoo whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma AT jeonseunghyun whichpatientsshouldwefollowupbeyond5yearsafterdefinitivetherapyforlocalizedrenalcellcarcinoma |